30 related articles for article (PubMed ID: 38520790)
1. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
Mpekris F; Papaphilippou PC; Panagi M; Voutouri C; Michael C; Charalambous A; Marinov Dinev M; Katsioloudi A; Prokopi-Demetriades M; Anayiotos A; Cabral H; Krasia-Christoforou T; Stylianopoulos T
ACS Nano; 2023 Dec; 17(24):24654-24667. PubMed ID: 38054429
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy.
Voutouri C; Mpekris F; Panagi M; Krolak C; Michael C; Martin JD; Averkiou MA; Stylianopoulos T
Acta Biomater; 2023 Sep; 167():121-134. PubMed ID: 37321529
[TBL] [Abstract][Full Text] [Related]
4. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
5. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.
Mpekris F; Panagi M; Voutouri C; Martin JD; Samuel R; Takahashi S; Gotohda N; Suzuki T; Papageorgis P; Demetriou P; Pierides C; Koumas L; Costeas P; Kojima M; Ishii G; Constantinidou A; Kataoka K; Cabral H; Stylianopoulos T
Adv Sci (Weinh); 2021 Feb; 8(3):2001917. PubMed ID: 33552852
[TBL] [Abstract][Full Text] [Related]
6. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
8. Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation.
Snipstad S; Sulheim E; de Lange Davies C; Moonen C; Storm G; Kiessling F; Schmid R; Lammers T
Expert Opin Drug Deliv; 2018 Dec; 15(12):1249-1261. PubMed ID: 30415585
[TBL] [Abstract][Full Text] [Related]
9. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.
Panagi M; Pilavaki P; Constantinidou A; Stylianopoulos T
Theranostics; 2022; 12(14):6106-6129. PubMed ID: 36168619
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
12. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
